Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial.
Saved in:
| Title: | Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial. |
|---|---|
| Authors: | Sylvie, Chevret1 (AUTHOR), Lila, Bouadma2,3 (AUTHOR), Claire, Dupuis3,4 (AUTHOR), Charles, Burdet3,5 (AUTHOR), Jean-François, Timsit2,3 (AUTHOR) Jean-francois.timsit@bch.aphp.fr, the COVIDICUS RCT group (AUTHOR), Beldjoudi, Naima (AUTHOR), Chevret, Sylvie (AUTHOR), Burdet, Charles (AUTHOR), Alloux, Céline (AUTHOR), Amerali, Fadila (AUTHOR), Andriss, Béatrice (AUTHOR), Baghli, Kamyl (AUTHOR), Brocvielle, Hélène (AUTHOR), Capelle, Florence (AUTHOR), Chibane, Ines (AUTHOR), Dalibey, Sarra (AUTHOR), Ettalhaoui, Nadia (AUTHOR), Lamri, Sabrine (AUTHOR), Maurer, Yohan (AUTHOR) |
| Source: | Annals of Intensive Care. 8/27/2023, Vol. 13 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
